TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Read more here.

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other AI stocks in news and ratings you should not miss. On February 19, CNBC reported ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on TEM stock.

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in Q4 ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other AI stocks in ...